Bastian Dehmel
Corporate Officer/Principal bij OCULIS HOLDING AG
Profiel
Bastian Dehmel is currently the Chief Development Officer at Oculis Holding AG.
Previously, he held the position of Executive Director-Global Medical Development at Amgen (Europe) GmbH from 2013 to 2017 and Chief Medical Officer at OxThera AB from 2017 to 2021.
Dr. Dehmel obtained a doctorate degree from Freie Universität Berlin.
Actieve functies van Bastian Dehmel
| Bedrijven | Functie | Begin |
|---|---|---|
| OCULIS HOLDING AG | Corporate Officer/Principal | 01-01-2022 |
Eerdere bekende functies van Bastian Dehmel
| Bedrijven | Functie | Einde |
|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Hoofd Techniek/Wetenschap/O&O | 01-12-2021 |
| Amgen (Europe) GmbH | Corporate Officer/Principal | 01-07-2017 |
Opleiding van Bastian Dehmel
| Freie Universität Berlin | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| OCULIS HOLDING AG | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
| Amgen (Europe) GmbH |
